Royalty Pharma plc - Common Stock (RPRX)

Historical Holders from Q1 2019 to Q3 2025

Symbol: RPRX on Nasdaq
Type / Class: Equity / Common Stock
Shares outstanding: 432,001,939
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 327,656,446
Holdings value: $11,558,447,601
% of all portfolios: 0.01%
Number of holders: 479
Number of buys: 290
Number of sells: -182
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Royalty Pharma plc - Common Stock (RPRX)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
Legorreta Pablo G.	19.74%		$3,372,819,557		103,112,796		Legorreta G. Pablo	16 May 2025
MORGAN STANLEY	9.2%		$1,394,427,274		38,907,011		Morgan Stanley	30 Jun 2025
Severgnini Achille G.	6.9%	-17.5%	$978,885,021	-$198,725,189	29,926,170	-16.9%	Severgnini Achille G.	30 Apr 2025
Capital International Investors	6.6%	+18.3%	$1,005,907,876	+$190,516,586	28,512,128	+23.4%	Capital International Investors	30 Sep 2025
FMR LLC	6.5%	-28.9%	$984,337,180	-$400,247,331	27,900,713	-28.9%	FMR LLC	30 Sep 2025
BlackRock, Inc.	5.7%		$832,319,492		25,445,414		BlackRock, Inc.	31 Dec 2024
GENERAL ATLANTIC, L.P.	3.2%		$510,500,301		14,243,870		General Atlantic, L.P.	30 Jun 2025
VANGUARD GROUP INC	2.52%		$385,841,061		10,936,538		The Vanguard Group	30 Sep 2025

Institutional Holders of Royalty Pharma plc - Common Stock (RPRX)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	327,656,446	$11,558,447,601	-$517,560,599	$8,890,560	$45,482,976	$35.28	479
2025 Q2	342,210,637	$12,333,363,729	+$949,776,240	$13,824,711	$70,074,747	$36.03	452
2025 Q1	317,255,108	$9,879,343,045	-$34,196,805	$29,287,104	$76,794,597	$31.13	444
2024 Q4	320,707,173	$8,183,523,072	+$144,649,409	$3,002,527	$12,951,427	$25.51	414
2024 Q3	312,434,792	$8,832,030,084	-$70,655,781	$1,343,775	$16,337,475	$28.29	391
2024 Q2	316,171,106	$8,334,967,211	+$126,311,822	$3,644,334	$7,903,089	$26.37	373
2024 Q1	311,994,207	$9,469,625,864	+$68,283,642	$7,164,283	$8,215,085	$30.37	375
2023 Q4	310,848,061	$8,731,929,890	+$90,598,401	$10,491,615	$15,092,757	$28.09	359
2023 Q3	300,556,312	$8,159,558,450	-$95,718,367	$5,037,184	$31,135,334	$27.14	312
2023 Q2	302,776,880	$9,312,865,143	+$35,406,560	$2,597,530	$13,012,242	$30.74	321
2023 Q1	301,740,017	$10,870,806,631	+$87,185,612	$1,949,223	$15,348,780	$36.03	331
2022 Q4	299,214,570	$11,818,548,636	+$83,591,490	$3,039,088	$18,894,512	$39.52	332
2022 Q3	298,186,963	$11,983,269,244	+$263,400,168	$3,588,000	$45,391,000	$40.18	311
2022 Q2	291,545,338	$12,256,604,812	+$918,924,477	$2,792,000	$45,554,000	$42.04	281
2022 Q1	270,383,631	$10,536,275,796	+$82,755,109	$3,549,000	$35,635,000	$38.96	272
2021 Q4	268,200,640	$10,687,984,091	+$139,946,049	$9,258,000	$45,732,000	$39.85	254
2021 Q3	265,367,304	$9,590,727,932	+$538,289,516	$9,829,800	$42,266,000	$36.14	226
2021 Q2	250,410,928	$10,263,954,175	+$118,347,007	$13,003,000	$32,854,000	$40.99	229
2021 Q1	246,400,511	$10,747,503,399	+$874,104,377	$11,045,000	$44,314,000	$43.62	208
2020 Q4	226,132,987	$11,317,812,164	+$1,961,711,795	$38,699,000	$16,993,000	$50.05	188
2020 Q3	155,310,287	$6,522,638,173	+$367,540,942	$6,150,000	$4,367,000	$42.07	129
2020 Q2	146,093,806	$7,034,558,503	+$7,034,558,867	$1,544,000	$2,616,000	$48.55	119
2020 Q1	15	$1,000				$66.67	1
2019 Q4	15	$1,000				$66.67	1
2019 Q3	15	$1,000				$66.67	1
2019 Q2	15	$1,000				$66.67	1
2019 Q1	15	$1,000				$66.67	1